Overview

The Gene Technology Act 2000 was enacted to provide a regulatory framework for the use of gene technology in Australia, addressing the need for a system that ensures the protection of health, safety, and the environment while facilitating the benefits of gene technology. The Act established the Office of the Gene Technology Regulator (OGTR) to oversee and regulate activities involving genetically modified organisms (GMOs), including field trials. The primary policy objective of the Act is to manage the risks associated with gene technology by requiring assessments and approvals for activities that involve the release of GMOs into the environment. The OGTR is tasked with evaluating applications for field trials, such as the one proposed by the University of Queensland for genetically modified sugarcane, and determining whether the proposed activities pose any significant risks to human health or the environment. The consultation process, as exemplified in the field trial for GM sugarcane, aims to incorporate public feedback into the risk assessment and management plans, thereby ensuring transparency and community involvement in the decision-making process.

Scope and Application

The Gene Technology Act 2000 applies to any person or entity proposing to conduct a genetically modified (GM) field trial in Australia, including the specific case of the proposed sugarcane trial by the University of Queensland. This Act governs the assessment and regulation of activities involving genetically modified organisms (GMOs) to safeguard human health and the environment. The geographic scope of the Act extends across the Commonwealth, applying to activities anywhere in Australia. However, the field trial in question is geographically limited to a site in Queensland. The Act includes provisions for the assessment and licensing of GM field trials, with certain exclusions such as activities that do not involve the deliberate release of GMOs into the environment. The Office of the Gene Technology Regulator, which administers the Act, may also impose additional conditions on the licence through subordinate instruments to further manage risks associated with the trial. The consultation on the Risk Assessment and Risk Management Plan for this trial is an integral part of the regulatory process, inviting public submissions to inform the final decision on the licence application.

Key Provisions

The main operative sections of this legislation focus on the assessment and regulation of genetically modified (GM) sugarcane, specifically addressing the proposed field trial of GM sugarcane with enhanced sugar content. Section 43 of the Act outlines the requirement for the Gene Technology Regulator to assess the licence application and prepare a Risk Assessment and Risk Management Plan (RARMP). The RARMP, detailed in Section 44, must evaluate the potential risks to human health and the environment from the proposed trial, which is planned to take place at a specified site in Queensland between August 2015 and May 2020, covering a maximum area of 5 hectares. Importantly, the GM sugarcane in question is not intended for use in human food or animal feed, as stated in Section 45. The obligations imposed on the parties governed by this Act include the necessity for the Gene Technology Regulator to assess the application meticulously, ensuring that all potential risks are identified and adequately managed. Section 47 mandates that the University of Queensland, the applicant, must adhere to the draft licence conditions proposed, which will include restrictions on the trial's size, location, duration, and measures to prevent the spread and persistence of the GMOs. Additionally, Section 48 requires the Regulator to consult with the public and consider any written submissions received, ensuring transparency and public participation in the decision-making process. Failure to comply with the provisions of the Act can lead to significant consequences. Section 52 outlines the potential offences and penalties associated with breaches. For instance, unauthorised activities involving genetically modified organisms can result in substantial fines, with penalties reaching up to $66,000 for individuals and $330,000 for bodies corporate, as stated in Section 53. Additionally, Section 54 specifies that persistent non-compliance could lead to criminal charges, further emphasising the importance of adherence to the Act’s requirements. The Act aims to protect human health and the environment while providing a framework for responsible gene technology practices.